A case of splenic low-grade mucinous cystadenocarcinoma resulting in pseudomyxoma peritonei.

Primary splenic mucinous cystadenocarcinoma (MCCa) is extremely rare, and only six cases appear to have been reported previously. We present herein a case of primary splenic MCCa resulting in pseudomyxoma peritonei (PMP). A 66-year-old Japanese woman presented to a hospital with a chief complaint of upper abdominal pain and a 7-year history of splenic cyst. Cyst rupture was noted on computed tomography, and splenectomy was performed. The abdominal cavity was filled with a large amount of gelatinous ascites, with the appearance of PMP. On the cut surface, multiple cysts containing mucinous material were found within and outside the spleen. Microscopically, splenic parenchyma was occupied by large mucinous pools focally lined with mucinous epithelial cells and mesothelial cell-like cells, which were considered benign. Outside the spleen, a low-grade MCCa component was found. No ectopic pancreatic or intestinal tissue was identified. Although most PMP cases are known to be caused by low-grade mucinous appendiceal tumor, the present case represents the first report of a splenic MCCa resulting in PMP.

[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].

UNLABELLED: We evaluated the effect of sorafenib and intermittent hepatic arterial infusion chemotherapy (HAIC) using cisplatin for unresectable advanced hepatocellular carcinoma (HCC). METHODS: 5 patients (4 male/1 female, median age: 73.0 years) with unresectable advanced HCC including portal vein tumor thrombus were treated with soraenib (400 mg/body, day 1-28) and cisplatin (20 mg/m2 HAIC, day 1, 8, 15). We assess efficacy and safety after 1 course of this therapy. RESULTS: Grade 3 adverse events occurred in 2 patients (1 serum bilirubin and aspartate aminotransferase (AST) elevation, 1 serum bilirubin elevation and hepatic encephalopathy). Grade 2 adverse events occurred in 4 patients (1 hypertension and nertropenia, 1 hypertension and thrombocytopenia, 1 hypertension and serum amylase elevation, and 1 abdominal pain). Grade 3 adverse events were improved by suspending this therapy, and completion of this therapy was achieved in all patients. After one course of this therapy, the clinical response was rated as 1 partial response (PR), 3-stable disease (SD), and 1 progressive disease (PD). CONCLUSION: Sorafenib and intermittent HAIC using cisplatin for unresectable advanced HCC was expected to be safe and effective treatment.

Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients.

One of the longstanding challenges in the treatment of pancreatic cancer, the fifth most common cancer worldwide, is to establish a simple and reliable diagnostic marker for the disease. This study examined whether or not the plasma levels of IgG antibodies (IgGs) reactive to peptides derived from the prostate stem cell antigen (PSCA), which is highly expressed in pancreatic cancer cells, were elevated in patients with pancreatic cancer. Fifty-seven kinds of peptides encoded by PSCA were tested for their reactivity to plasma IgGs of pancreatic cancer patients. The results showed that the levels of IgGs specific to each of the 10 different peptides in the plasma of pancreatic cancer patients were significantly higher than those of non-cancer subjects. Eighty percent of subjects with and 18% of subjects without pancreatic cancer were diagnosed as having pancreatic cancer, respectively, when those cases showing significantly elevated levels of IgGs against at least one of the three peptides of PSCA at positions 2-11, 85-95, and 109-118 were judged as positive for pancreatic cancer. These results indicate that the measurement of IgGs reactive to these PSCA-derived peptides can provide novel information on the host-tumor interaction in pancreatic cancer, and could potentially be used as a new diagnostic tool to screen for pancreatic cancer.

Development of a new diagnostic tool for pancreatic cancer: simultaneous measurement of antibodies against peptides recognized by cytotoxic T lymphocytes.

One of the longstanding challenges in the treatment of pancreatic cancer, the fifth most common cancer worldwide, is to establish a simple and reliable diagnostic marker for the disease. This study examined whether or not the simultaneous measurement of plasma levels of IgG antibodies (IgGs) reactive to peptides recognized by cytotoxic T lymphocytes was useful for screening of pancreatic cancer. Sixty-three kinds of peptides were tested for their reactivity to plasma IgGs of pancreatic cancer patients with Luminex system followed by discriminatory analysis of the results using the Statistical Discovery Software. Under these circumstances, 83% of subjects with pancreatic cancer and 12% of healthy donors were diagnosed as having pancreatic cancer, respectively. These results suggest that the simultaneous measurement of IgGs reactive to these peptides could potentially be useful as a new diagnostic tool to screen for pancreatic cancer.